RETRACTED ARTICLE: Observational study:daily treatment with a new compound “tradamixina” plus serenoa repens for two monthsimproved the lower urinary tract symptoms

BMC Surgery

Research Article

Bruno Amato¹  Ester Illiano²  Giuseppe Romeo²  Domenico Prezioso²  Antonio Ruffo²  Fabrizio Iacono² 

[1] Department of General, Geriatric, Oncologic Surgery and Advanced Technologies, University “Federico II” of Naples, Via Pansini, 5 - 80131, Naples, Italy;Department of Urology, University Federico II of Naples, Via S. Pansini, 5 – 80131, Naples, Italy;

关键词: Benign Prostatic Hyperplasia;    Lower Urinary Tract Symptom;    International Prostate Symptom Score;    Dutasteride;    Storage Symptom;   

DOI  :  10.1186/1471-2482-12-S1-S22

来源: Springer

【 摘 要 】

BackgroundLower urinary tract symptoms (LUTS) are associated with great emotional coststo individuals and substantial economic costs to society. This study seeks toevaluate the effect of a new natural compound “Tradamixina plus Serenoa Repens” inorder to improve lower urinary tract symptoms.Methods100 patients (≥45years) who had had LUTS/BPH for >6 mo at screening andwith IPSS -The international Prostate symptom scores- ≥13 and maximum urinary flowrate (Qmax) ≥4 to ≤15 ml/s. were recruited. The compound “Tradamixina plus SerenoaRepens” (80 mg of Alga Ecklonia Bicyclis, 100 mg of Tribulus Terrestris and 100 mgof D-Glucosamine and N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens) wasadministered daily for 2 months. At visit and after 60 days of treatment patientswere evaluated by means of detailed medical urological history, clinicalexamination, laboratory investigations (total PSA), and instrumental examinationlike urolfowmetry. Efficacy measures included IPSS-International Prostate Sympto,BPH Impact Index (BII), Quality-of-Life (QoL) Index. Measures were assessed atbaseline and end point (12 wk or end of therapy) and also at screening, 1 and 4 wkfor IPSS, and 4 wk for BII. Statistical significance was interpreted only if theresults of the preceding analysis were significant at the 0.05 level.ResultsAfter 2 months of treatment the change from baseline to week 12 relative to“Tradamixina plus Seronea Repens” in total IPSS and Qol was statisticallysignificant. Differences from baseline in BII were statistically significant for“Tradamixina plus Seronea Repens” above all differences in BII were alsosignificant at 4 wk (LSmean ± SE: -0.8 ± 0.2). In the distribution of subjectsover the PGI-I and CGI-I response categories were significant for”Tradamixina plusSeronea Repens” (PGI-I: p = 0.001; CGI-I). We also observed a decrease of totalPSA.ConclusionThe daily treatment with a new compound “Tradamixina plus Serenoa Repens” for2 months improved the male sexual function , it improved the bother symptoms whichaffect the patient’s quality of life , improved uroflowmetric parameters, and wealso observed a decrease of serum PSA level.

【 授权许可】

Unknown   
© Iacono et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This isan Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.